Barclays analyst Gena Wang maintains $Biomarin Pharmaceutical (BMRN.US)$ with a buy rating, and maintains the target price at $86.
According to TipRanks data, the analyst has a success rate of 43.6% and a total average return of 7.6% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Biomarin Pharmaceutical (BMRN.US)$'s main analysts recently are as follows:
BioMarin has delivered a strong quarter, with a slight increase in guidance for both revenue and earnings. Analysts believe that the value of the company's enzyme replacement therapy sector alone justifies the current share price. Furthermore, the impending clinical trials for BMN333 in early 2025 are seen as a potential major contributor to the company's value, both in maintaining market share in its current indications and potentially expanding into additional ones where Voxzogo is under investigation.
BioMarin's third quarter financial results exceeded expectations on both the top and bottom lines, with a slight increase in the fiscal 2024 guidance for all main metrics. Although Voxzogo's performance fell short of forecasts, this was balanced by outcomes from the company's enzyme replacement therapy business that surpassed expectations.
The firm identifies an appealing entry point at the current share levels for BioMarin, highlighting the company's robust base business and the prospect of significant operating margin growth in the coming years.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
巴克萊銀行分析師Gena Wang維持$拜瑪林製藥 (BMRN.US)$買入評級，維持目標價86美元。
根據TipRanks數據顯示，該分析師近一年總勝率為43.6%，總平均回報率為7.6%。
此外，綜合報道，$拜瑪林製藥 (BMRN.US)$近期主要分析師觀點如下：
BioMarin交出了一個強勁的季度，營收和收益均略有增長。分析師認爲，公司的酶替代療法板塊的價值已經足以支持目前的股價。此外，2025年初關於BMN333的即將進行的臨床試驗被視爲公司價值的一個潛在主要貢獻者，無論是在維持當前適應症的市場份額方面還是在可能擴展至Voxzogo正在接受調查的其他適應症方面。
BioMarin第三季度財務業績在各項主要指標上均超出預期，2024財年指引對所有主要指標均有輕微增長。雖然Voxzogo的表現低於預期，但公司酶替代療法業務的業績超過預期，對公司的貢獻起到平衡作用。
該公司確定了BioMarin目前股價的吸引人入場點，強調公司穩固的基礎業務和未來幾年中營業利潤率的可觀增長前景。
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
